ProCE Banner Activity

MAINTAIN: Phase II Study of Switching ET ± Ribociclib for HR+/HER2- Metastatic Breast Cancer After Failure of Previous ET + CDK4/6i

Slideset Download
Ribociclib combined with switching endocrine therapy improved PFS in patients with HR-positive/HER2-negative metastatic breast cancer who progressed on prior standard of care CDK4/6 inhibition with endocrine therapy.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab